Intellia Therapeutics
Frank Verwiel is a board member at Intellia Therapeutics. Frank has also served on the boards of ObsEva SA, Achillion Pharmaceuticals, Inc., AveXis, Inc., and Bavarian Nordic. Frank was previously the president and CEO of Aptalis Pharma and vice-president of global marketing at Merck.
Frank Verwiel has a MBA from INSEAD, a M.D. from Erasmus University Rotterdam, and a PPL in Business Administration and Management, General from Harvard Business School.
This person is not in the org chart
This person is not in any offices
Intellia Therapeutics
9 followers
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.